Valsartan Alone and in Combination with Hydrochlorothiazide in General Practice View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2000-07

AUTHORS

J. Scholze, G. Probst, K. Bertsch

ABSTRACT

Objectives: To assess the efficacy and tolerability of valsartan and valsartan plus hydrochlorothiazide (HCTZ), given alone or as part of a combination regimen with other antihypertensive agents, in a large number of general practice patients with essential hypertension. Design: In two open, noncomparative, multicentre postmarketing surveillance (PMS) studies, 26 488 patients were treated with valsartan for 6 months (trial 1) and 28 440 with the fixed combination valsartan/HCTZ for 3 months (trial 2). Main Outcome Measures: Assessments at baseline and study endpoints included systolic (SBP) and diastolic blood pressures (DBP), and analysis of adverse events. Results: A total of 15 867 patients (61.0%) in trial 1 received valsartan (mostly as 80mg once daily) and 21 558 patients (75.8%) in trial 2 received valsartan/ HCTZ (80/12.5mg once daily) without additional antihypertensive agents. In the two studies, marked reductions in SBP and DBP were observed [mean SBP −29.5mm Hg (trial 1) and −27.3mm Hg (trial 2); mean DBP −15.6mm Hg (trial 1) and −14.7mm Hg (trial 2)]. The results were almost identical in patients treated with valsartan alone or valsartan/HCTZ, compared with those who also received additional antihypertensive agents. Overall, tolerability was excellent, with 97.5% of patients in trial 1 and 99.3% of patients in trial 2 reporting no adverse events. Hitherto unknown adverse effects were not observed. Conclusions: In these large PMS studies, valsartan and valsartan/HCTZ demonstrated excellent efficacy and tolerability in general practice patients with primary hypertension, irrespective of age, gender, concomitant diseases or severity of the underlying hypertension. More... »

PAGES

1-7

Journal

TITLE

Clinical Drug Investigation

ISSUE

1

VOLUME

20

Author Affiliations

Identifiers

URI

http://scigraph.springernature.com/pub.10.2165/00044011-200020010-00001

DOI

http://dx.doi.org/10.2165/00044011-200020010-00001

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1004560003


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Medical University Clinic Charit\u00e9, Berlin, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Scholze", 
        "givenName": "J.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.467675.1", 
          "name": [
            "Novartis Pharma, Nuremberg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Probst", 
        "givenName": "G.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.467675.1", 
          "name": [
            "Novartis Pharma, Nuremberg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bertsch", 
        "givenName": "K.", 
        "id": "sg:person.016562672447.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016562672447.53"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s0149-2918(96)80040-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003250824"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(86)90486-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011790960"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00004872-199609000-00016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013550162"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00004872-199609000-00016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013550162"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00004872-199609000-00016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013550162"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/archinte.1990.00390180019003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014809447"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.302.6770.223", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022444780"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm198601023140119", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023374438"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02570503", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024087987", 
          "https://doi.org/10.1007/bf02570503"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1527-3466.1995.tb00305.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024763463"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1527-3466.1995.tb00305.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024763463"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.293.6541.219", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026935718"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/j.1552-4604.1997.tb04767.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033562921"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/archinte.1996.00440030072009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034138509"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0149-2918(96)80061-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038730772"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.288.6421.879", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045629995"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.jhh.1000482", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047926085", 
          "https://doi.org/10.1038/sj.jhh.1000482"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.jhh.1000482", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047926085", 
          "https://doi.org/10.1038/sj.jhh.1000482"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cpt197925133", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048547263"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.311.7000.293", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1062772785"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.311.7000.293", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1062772785"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074369925", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079416725", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079419051", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082658982", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083221527", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2000-07", 
    "datePublishedReg": "2000-07-01", 
    "description": "Objectives: To assess the efficacy and tolerability of valsartan and valsartan plus hydrochlorothiazide (HCTZ), given alone or as part of a combination regimen with other antihypertensive agents, in a large number of general practice patients with essential hypertension. Design: In two open, noncomparative, multicentre postmarketing surveillance (PMS) studies, 26 488 patients were treated with valsartan for 6 months (trial 1) and 28 440 with the fixed combination valsartan/HCTZ for 3 months (trial 2). Main Outcome Measures: Assessments at baseline and study endpoints included systolic (SBP) and diastolic blood pressures (DBP), and analysis of adverse events. Results: A total of 15 867 patients (61.0%) in trial 1 received valsartan (mostly as 80mg once daily) and 21 558 patients (75.8%) in trial 2 received valsartan/ HCTZ (80/12.5mg once daily) without additional antihypertensive agents. In the two studies, marked reductions in SBP and DBP were observed [mean SBP \u221229.5mm Hg (trial 1) and \u221227.3mm Hg (trial 2); mean DBP \u221215.6mm Hg (trial 1) and \u221214.7mm Hg (trial 2)]. The results were almost identical in patients treated with valsartan alone or valsartan/HCTZ, compared with those who also received additional antihypertensive agents. Overall, tolerability was excellent, with 97.5% of patients in trial 1 and 99.3% of patients in trial 2 reporting no adverse events. Hitherto unknown adverse effects were not observed. Conclusions: In these large PMS studies, valsartan and valsartan/HCTZ demonstrated excellent efficacy and tolerability in general practice patients with primary hypertension, irrespective of age, gender, concomitant diseases or severity of the underlying hypertension.", 
    "genre": "research_article", 
    "id": "sg:pub.10.2165/00044011-200020010-00001", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1100199", 
        "issn": [
          "1173-2563", 
          "1179-1918"
        ], 
        "name": "Clinical Drug Investigation", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "20"
      }
    ], 
    "name": "Valsartan Alone and in Combination with Hydrochlorothiazide in General Practice", 
    "pagination": "1-7", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "15bade2c49728be522dd33cabf22c6828c77e5587e704e2c7f01b6f9f26d28f6"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.2165/00044011-200020010-00001"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1004560003"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.2165/00044011-200020010-00001", 
      "https://app.dimensions.ai/details/publication/pub.1004560003"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T12:40", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000363_0000000363/records_70049_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.2165/00044011-200020010-00001"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00044011-200020010-00001'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00044011-200020010-00001'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00044011-200020010-00001'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00044011-200020010-00001'


 

This table displays all metadata directly associated to this object as RDF triples.

135 TRIPLES      21 PREDICATES      48 URIs      19 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.2165/00044011-200020010-00001 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N4596cfc57998420890bed9e9eacd34b9
4 schema:citation sg:pub.10.1007/bf02570503
5 sg:pub.10.1038/sj.jhh.1000482
6 https://app.dimensions.ai/details/publication/pub.1074369925
7 https://app.dimensions.ai/details/publication/pub.1079416725
8 https://app.dimensions.ai/details/publication/pub.1079419051
9 https://app.dimensions.ai/details/publication/pub.1082658982
10 https://app.dimensions.ai/details/publication/pub.1083221527
11 https://doi.org/10.1001/archinte.1990.00390180019003
12 https://doi.org/10.1001/archinte.1996.00440030072009
13 https://doi.org/10.1002/cpt197925133
14 https://doi.org/10.1002/j.1552-4604.1997.tb04767.x
15 https://doi.org/10.1016/s0140-6736(86)90486-1
16 https://doi.org/10.1016/s0149-2918(96)80040-3
17 https://doi.org/10.1016/s0149-2918(96)80061-0
18 https://doi.org/10.1056/nejm198601023140119
19 https://doi.org/10.1097/00004872-199609000-00016
20 https://doi.org/10.1111/j.1527-3466.1995.tb00305.x
21 https://doi.org/10.1136/bmj.288.6421.879
22 https://doi.org/10.1136/bmj.293.6541.219
23 https://doi.org/10.1136/bmj.302.6770.223
24 https://doi.org/10.1136/bmj.311.7000.293
25 schema:datePublished 2000-07
26 schema:datePublishedReg 2000-07-01
27 schema:description Objectives: To assess the efficacy and tolerability of valsartan and valsartan plus hydrochlorothiazide (HCTZ), given alone or as part of a combination regimen with other antihypertensive agents, in a large number of general practice patients with essential hypertension. Design: In two open, noncomparative, multicentre postmarketing surveillance (PMS) studies, 26 488 patients were treated with valsartan for 6 months (trial 1) and 28 440 with the fixed combination valsartan/HCTZ for 3 months (trial 2). Main Outcome Measures: Assessments at baseline and study endpoints included systolic (SBP) and diastolic blood pressures (DBP), and analysis of adverse events. Results: A total of 15 867 patients (61.0%) in trial 1 received valsartan (mostly as 80mg once daily) and 21 558 patients (75.8%) in trial 2 received valsartan/ HCTZ (80/12.5mg once daily) without additional antihypertensive agents. In the two studies, marked reductions in SBP and DBP were observed [mean SBP −29.5mm Hg (trial 1) and −27.3mm Hg (trial 2); mean DBP −15.6mm Hg (trial 1) and −14.7mm Hg (trial 2)]. The results were almost identical in patients treated with valsartan alone or valsartan/HCTZ, compared with those who also received additional antihypertensive agents. Overall, tolerability was excellent, with 97.5% of patients in trial 1 and 99.3% of patients in trial 2 reporting no adverse events. Hitherto unknown adverse effects were not observed. Conclusions: In these large PMS studies, valsartan and valsartan/HCTZ demonstrated excellent efficacy and tolerability in general practice patients with primary hypertension, irrespective of age, gender, concomitant diseases or severity of the underlying hypertension.
28 schema:genre research_article
29 schema:inLanguage en
30 schema:isAccessibleForFree false
31 schema:isPartOf N287526ae5c7348c995b998c80d62fd1f
32 N336234ae1c30444883a26b24d7663c58
33 sg:journal.1100199
34 schema:name Valsartan Alone and in Combination with Hydrochlorothiazide in General Practice
35 schema:pagination 1-7
36 schema:productId N083234aee1cb410e9c201fabee693b92
37 N71ede9fe825144c6a20dc8088a5e6eee
38 Nb0e13a2a73064326835e6364215d7e16
39 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004560003
40 https://doi.org/10.2165/00044011-200020010-00001
41 schema:sdDatePublished 2019-04-11T12:40
42 schema:sdLicense https://scigraph.springernature.com/explorer/license/
43 schema:sdPublisher Naa4bfe7b091b414ba549ba0f6afab42b
44 schema:url http://link.springer.com/10.2165/00044011-200020010-00001
45 sgo:license sg:explorer/license/
46 sgo:sdDataset articles
47 rdf:type schema:ScholarlyArticle
48 N083234aee1cb410e9c201fabee693b92 schema:name readcube_id
49 schema:value 15bade2c49728be522dd33cabf22c6828c77e5587e704e2c7f01b6f9f26d28f6
50 rdf:type schema:PropertyValue
51 N287526ae5c7348c995b998c80d62fd1f schema:volumeNumber 20
52 rdf:type schema:PublicationVolume
53 N336234ae1c30444883a26b24d7663c58 schema:issueNumber 1
54 rdf:type schema:PublicationIssue
55 N411acfa0357c40569a922e79df80fd35 schema:affiliation https://www.grid.ac/institutes/grid.467675.1
56 schema:familyName Probst
57 schema:givenName G.
58 rdf:type schema:Person
59 N4596cfc57998420890bed9e9eacd34b9 rdf:first Neb4fea05ec5145dcb342fbc55c35f2b7
60 rdf:rest N97f19411112448759518bafc0358ffdc
61 N71ede9fe825144c6a20dc8088a5e6eee schema:name doi
62 schema:value 10.2165/00044011-200020010-00001
63 rdf:type schema:PropertyValue
64 N97f19411112448759518bafc0358ffdc rdf:first N411acfa0357c40569a922e79df80fd35
65 rdf:rest Na9528572716a469eaf726abdc5261ae3
66 Na9528572716a469eaf726abdc5261ae3 rdf:first sg:person.016562672447.53
67 rdf:rest rdf:nil
68 Naa4bfe7b091b414ba549ba0f6afab42b schema:name Springer Nature - SN SciGraph project
69 rdf:type schema:Organization
70 Nb0e13a2a73064326835e6364215d7e16 schema:name dimensions_id
71 schema:value pub.1004560003
72 rdf:type schema:PropertyValue
73 Nd1915a830425485daddbb9258680bc8c schema:name Medical University Clinic Charité, Berlin, Germany
74 rdf:type schema:Organization
75 Neb4fea05ec5145dcb342fbc55c35f2b7 schema:affiliation Nd1915a830425485daddbb9258680bc8c
76 schema:familyName Scholze
77 schema:givenName J.
78 rdf:type schema:Person
79 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
80 schema:name Medical and Health Sciences
81 rdf:type schema:DefinedTerm
82 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
83 schema:name Clinical Sciences
84 rdf:type schema:DefinedTerm
85 sg:journal.1100199 schema:issn 1173-2563
86 1179-1918
87 schema:name Clinical Drug Investigation
88 rdf:type schema:Periodical
89 sg:person.016562672447.53 schema:affiliation https://www.grid.ac/institutes/grid.467675.1
90 schema:familyName Bertsch
91 schema:givenName K.
92 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016562672447.53
93 rdf:type schema:Person
94 sg:pub.10.1007/bf02570503 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024087987
95 https://doi.org/10.1007/bf02570503
96 rdf:type schema:CreativeWork
97 sg:pub.10.1038/sj.jhh.1000482 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047926085
98 https://doi.org/10.1038/sj.jhh.1000482
99 rdf:type schema:CreativeWork
100 https://app.dimensions.ai/details/publication/pub.1074369925 schema:CreativeWork
101 https://app.dimensions.ai/details/publication/pub.1079416725 schema:CreativeWork
102 https://app.dimensions.ai/details/publication/pub.1079419051 schema:CreativeWork
103 https://app.dimensions.ai/details/publication/pub.1082658982 schema:CreativeWork
104 https://app.dimensions.ai/details/publication/pub.1083221527 schema:CreativeWork
105 https://doi.org/10.1001/archinte.1990.00390180019003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014809447
106 rdf:type schema:CreativeWork
107 https://doi.org/10.1001/archinte.1996.00440030072009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034138509
108 rdf:type schema:CreativeWork
109 https://doi.org/10.1002/cpt197925133 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048547263
110 rdf:type schema:CreativeWork
111 https://doi.org/10.1002/j.1552-4604.1997.tb04767.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1033562921
112 rdf:type schema:CreativeWork
113 https://doi.org/10.1016/s0140-6736(86)90486-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011790960
114 rdf:type schema:CreativeWork
115 https://doi.org/10.1016/s0149-2918(96)80040-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003250824
116 rdf:type schema:CreativeWork
117 https://doi.org/10.1016/s0149-2918(96)80061-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038730772
118 rdf:type schema:CreativeWork
119 https://doi.org/10.1056/nejm198601023140119 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023374438
120 rdf:type schema:CreativeWork
121 https://doi.org/10.1097/00004872-199609000-00016 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013550162
122 rdf:type schema:CreativeWork
123 https://doi.org/10.1111/j.1527-3466.1995.tb00305.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1024763463
124 rdf:type schema:CreativeWork
125 https://doi.org/10.1136/bmj.288.6421.879 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045629995
126 rdf:type schema:CreativeWork
127 https://doi.org/10.1136/bmj.293.6541.219 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026935718
128 rdf:type schema:CreativeWork
129 https://doi.org/10.1136/bmj.302.6770.223 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022444780
130 rdf:type schema:CreativeWork
131 https://doi.org/10.1136/bmj.311.7000.293 schema:sameAs https://app.dimensions.ai/details/publication/pub.1062772785
132 rdf:type schema:CreativeWork
133 https://www.grid.ac/institutes/grid.467675.1 schema:alternateName Novartis (Germany)
134 schema:name Novartis Pharma, Nuremberg, Germany
135 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...